Olaratumab - really a breakthrough for soft-tissue sarcomas?
Tools
Judson, I., van der Graaf, W. T.
(2016)
Olaratumab - really a breakthrough for soft-tissue sarcomas?
NATURE REVIEWS CLINICAL ONCOLOGY, 13 (9).
pp. 535-536.
ISSN 1759-4774
Full text not available from this repository.
Abstract
In a recent study, the addition of olaratumab to doxorubicin chemotherapy for patients with soft-tissue sarcoma resulted in prolongation of progression-free survival by only 2.5 months, but an overall survival benefit of 11.8 months; the large disparity between these outcomes raises important questions. We discuss these results in relation to those of other trials, and the implications for sarcoma therapy.
Item Type: | Editorial |
---|---|
Authors (ICR Faculty only): | Judson, Ian and van der Graaf, Winette |
All Authors: | Judson, I., van der Graaf, W. T. |
Additional Information: | ISI Document Delivery No.: DU4HS Times Cited: 0 Cited Reference Count: 8 Judson, Ian van der Graaf, Winette T. 0 NATURE PUBLISHING GROUP NEW YORK NAT REV CLIN ONCOL |
Uncontrolled Keywords: | CONTROLLED PHASE-3 TRIAL |
Research teams: | ICR divisions > Cancer Therapeutics > Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group) ICR divisions > Clinical Studies > Sarcoma Clinical Trials ICR divisions > Clinical Studies > Clinical and Translational Sarcoma |
Depositing User: | Barry Jenkins |
Date Deposited: | 18 Oct 2016 09:05 |
Last Modified: | 18 Oct 2016 09:05 |
URI: | http://publications.icr.ac.uk/id/eprint/15341 |
Actions (login required)
![]() |
View Item |